GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson’s disease
Brain · 2023
DOI: 10.1093/brain/awac413 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Brain, 2023. Verfasst von Konstantin Senkevich und 28 weiteren Autor:innen. Beteiligte Einrichtung: The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal H3A 2B4, Canada. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIMH NIH HHS, NIA NIH HHS, NIDA NIH HHS.
Abstract (Originalsprache)
The association between glucocerebrosidase, encoded by GBA, and Parkinson’s disease (PD) highlights the role of the lysosome in PD pathogenesis. Genome-wide association studies in PD have revealed multiple associated loci, including the GALC locus on chromosome 14. GALC encodes the lysosomal enzyme galactosylceramidase, which plays a pivotal role in the glycosphingolipid metabolism pathway. It is still unclear whether GALC is the gene driving the association in the chromosome 14 locus and, if so, by which mechanism. We first aimed to examine whether variants in the GALC locus and across the genome are associated with galactosylceramidase activity. We performed a genome-wide association study in two independent cohorts from (i) Columbia University; and (ii) the Parkinson’s Progression Markers Initiative study, followed by a meta-analysis with a total of 976 PD patients and 478 controls with available data on galactosylceramidase activity. We further analysed the effects of common GALC variants on expression and galactosylceramidase activity using genomic colocalization methods. Mendelian randomization was used to study whether galactosylceramidase activity may be causal in PD. To study the role of rare GALC variants, we analysed sequencing data from 5028 PD patients and 5422 controls. Additionally, we studied the functional impact of GALC knockout on alpha-synuclein accumulation and on glucocerebrosidase activity in neuronal cell models and performed in silico structural analysis of common GALC variants associated with altered galactosylceramidase activity. The top hit in PD genome-wide association study in the GALC locus, rs979812, is associated with increased galactosylceramidase activity (b = 1.2; SE = 0.06; P = 5.10 × 10−95). No other variants outside the GALC locus were associated with galactosylceramidase activity. Colocalization analysis demonstrated that rs979812 was also associated with increased galactosylceramidase expression. Mendelian randomization suggested that increased galactosylceramidase activity may be causally associated with PD (b = 0.025, SE = 0.007, P = 0.0008). We did not find an association between rare GALC variants and PD. GALC knockout using CRISPR–Cas9 did not lead to alpha-synuclein accumulation, further supporting that increased rather than reduced galactosylceramidase levels may be associated with PD. The structural analysis demonstrated that the common variant p.I562T may lead to improper maturation of galactosylceramidase affecting its activity. Our results nominate GALC as the gene associated with PD in this locus and suggest that the association of variants in the GALC locus may be driven by their effect of increasing galactosylceramidase expression and activity. Whether altering galactosylceramidase activity could be considered as a therapeutic target should be further studied.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal H3A 2B4, Canada.
- Department of Neurology and Neurosurgery, McGill University, Montréal H3A 2B4, Canada.
- Early Drug Discovery Unit (EDDU), Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal H3A 2B4, Canada.
- Department of Physiology, McGill University, Montréal H3A 1A1, Canada.
- Department of Human Genetics, McGill University, Montréal H3A 1A1, Canada.
- Center of Molecular Biotechnology, Russian State Agrarian University-Moscow Timiryazev Agricultural Academy, Moscow 127550, Russia.
ORCID-Profile: Yves Dauvilliers, Ming Sum Ruby Chiang, Cornelis Blauwendraat, Edward A Fon, Ziv Gan-Or
Förderung
- NIMH NIH HHS
- NIA NIH HHS
- NIDA NIH HHS
- NINDS NIH HHS
- NCATS NIH HHS
- Michael J. Fox Foundation
- Canadian Consortium on Neurodegeneration in Aging
- Canada First Research Excellence Fund
Zitieren
APA
Senkevich, K., Zorca, C. E., Dworkind, A., Rudakou, U., Somerville, E., Yu, E., Ermolaev, A., Nikanorova, D., Ahmad, J., Ruskey, J. A., Asayesh, F., Spiegelman, D., Fahn, S., Waters, C., Monchi, O., Dauvilliers, Y., Dupré, N., Greenbaum, L., Hassin-Baer, S., …, & Gan-Or, Z. (2023). GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson’s disease. Brain. https://doi.org/10.1093/brain/awac413
Vancouver
Senkevich K, Zorca CE, Dworkind A, Rudakou U, Somerville E, Yu E, et al. GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson’s disease. Brain. 2023. doi:10.1093/brain/awac413
BibTeX
@article{Senkevich2023,
author = {Senkevich, Konstantin and Zorca, Cornelia E and Dworkind, Aliza and Rudakou, Uladzislau and Somerville, Emma and Yu, Eric and Ermolaev, Alexey and Nikanorova, Daria and Ahmad, Jamil and Ruskey, Jennifer A and Asayesh, Farnaz and Spiegelman, Dan and Fahn, Stanley and Waters, Cheryl and Monchi, Oury and Dauvilliers, Yves and Dupré, Nicolas and Greenbaum, Lior and Hassin-Baer, Sharon and Grenn, Francis P and Chiang, Ming Sum Ruby and Sardi, S Pablo and Vanderperre, Benoît and Blauwendraat, Cornelis and Trempe, Jean-François and Fon, Edward A and Durcan, Thomas M and Alcalay, Roy N and Gan-Or, Ziv},
title = {GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson’s disease},
journal = {Brain},
year = {2023},
doi = {10.1093/brain/awac413}
}
EUVIMED